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Abstract
Objective Chemokine pathways are co-opted by
pancreatic adenocarcinoma (PDAC) to facilitate myeloid
cell recruitment from the bone marrow to establish an
immunosuppressive tumour microenvironment (TME).
Targeting tumour-associated CXCR2+neutrophils (TAN)
or tumour-associated CCR2+ macrophages (TAM) alone
improves antitumour immunity in preclinical models.
However, a compensatory influx of an alternative myeloid
subset may result in a persistent immunosuppressive
TME and promote therapeutic resistance. Here, we show
CCR2 and CXCR2 combined blockade reduces total
tumour-infiltrating myeloids, promoting a more robust
antitumour immune response in PDAC compared with
either strategy alone.
Methods Blood, bone marrow and tumours were
analysed from PDAC patients and controls. Treatment
response and correlative studies were performed
in mice with established orthotopic PDAC tumours
treated with a small molecule CCR2 inhibitor
(CCR2i) and CXCR2 inhibitor (CXCR2i), alone and in
combination with chemotherapy.
Results A systemic increase in CXCR2+ TAN
correlates with poor prognosis in PDAC, and patients
receiving CCR2i showed increased tumour-infiltrating
CXCR2+ TAN following treatment. In an orthotopic
PDAC model, CXCR2 blockade prevented neutrophil
mobilisation from the circulation and augmented
chemotherapeutic efficacy. However, depletion of
either CXCR2+ TAN or CCR2+ TAM resulted in a
compensatory response of the alternative myeloid
subset, recapitulating human disease. This was
overcome by combined CCR2i and CXCR2i, which
augmented antitumour immunity and improved
response to FOLFIRINOX chemotherapy.
Conclusion Dual targeting of CCR2+ TAM and
CXCR2+ TAN improves antitumour immunity and
chemotherapeutic response in PDAC compared with
either strategy alone.

Introduction
Pancreatic adenocarcinoma (PDAC) is the fourth
leading cause of cancer-related deaths, with

incidence expected to increase over the coming
decade.1 2 Despite advances using conventional
chemotherapy in PDAC, 5-year survival remains
a dismal 8%, and the immunosuppressive tumour
microenvironment (TME) remains a significant
barrier to effective treatment. This fibrotic stromal
compartment is infiltrated by tumour-associated
macrophages (TAM) and tumour-associated neutrophils (TAN) that are recruited from the bone marrow
to facilitate PDAC immune evasion.3 4 Thus, therapies disrupting myeloid trafficking represent an
attractive modality to restore antitumour immunity.
Neutrophils are the most abundant myeloid
population, and a systemic granulocytic expansion
has been reported in cancer, with intratumoural
accumulation of TAN (CD11b+, CD14−, CD15+
and CD66b+) correlating with poor prognosis.5 6 CXCR2 and its ligands in the ELR+ chemokine family, including CXCL1, CXCL2, CXCL3,
CXCL5, CXCL7 and CXCL8, are responsible for
recruiting neutrophils under normal physiological
conditions and have been implicated in tumour-mediated TAN mobilisation.7 8 Tumour-bearing
animals also demonstrate a systemic increase in
TAN (CD11b+, Gr1High, Ly6CLow and Ly6GHigh),
and targeting TAN has been shown to increase
tumour-infiltrating lymphocytes (TIL) and improve
response to checkpoint blockade in preclinical
studies.9–13
Our previous work found PDAC expression of
CCL2 results in mobilisation of CCR2+ inflammatory monocytes from the bone marrow to the tumour,
where they become immunosuppressive TAM.14 A
dense TAM (CD11b+, CD115+, CD14+, CD15−
and CD68+) infiltrate has been associated with
decreased survival in multiple malignancies and
targeting CCR2+ TAM (CD11b+, Gr1Low, Ly6Glow,
Ly6CMid and F4/80High) reduces tumour progression
in murine cancer models.14–18 Based on these findings, we conducted a clinical trial (NCT01413022)
in patients with non-metastatic PDAC using
the orally dosed, small molecule CCR2 inhibitor (CCR2i) PF-04136309 in combination with
FOLFIRINOX that demonstrated a favourable
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Targeting both tumour-associated CXCR2+
neutrophils and CCR2+ macrophages disrupts
myeloid recruitment and improves chemotherapeutic
responses in pancreatic ductal adenocarcinoma
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Significance of this study

What are the new findings?
►► Treatment with a CCR2 inhibitor results in a compensatory
influx of CXCR2+ TAN in patients with human PDAC.
+
►► A systemic increase in CXCR2 neutrophils correlates with
poor prognosis in PDAC.
►► CXCR2 blockade, both alone and in combination with
FOLFIRINOX chemotherapy, prevents TAN mobilisation
from the peripheral blood and increases effector tumourinfiltrating T cells in an orthotopic PDAC model.
►► Myeloid substitution is recapitulated in an orthotopic PDAC
model, and combining CCR2 plus CXCR2 blockade reduces
total tumour-infiltrating myeloid cells, enhancing antitumour
immunity and chemotherapeutic responses compared with
either therapy alone.
How might it impact on clinical practice in the foreseeable
future?
Targeting the predominant tumour-infiltrating myeloid lineages
in combination may represent an optimal approach to reverse
the immunosuppressive TME and enhance chemotherapeutic
responses in PDAC.

clinical response rate compared with chemotherapy alone.19
However, tumour-mediated recruitment of bone marrow-derived cells is an elaborate process, and disruption by immunomodulatory therapies is not without a compensatory response.
Several studies have found that depleting TAM results in a
compensatory TAN influx, which may contribute to treatment
failure following CCR2 blockade.20 21 Thus, it remains unclear if
disrupting a single myeloid subset is the most effective approach
to targeting the immunosuppressive TME.
Here we report that targeting CCR2+ TAM results in
a compensatory neutrophil influx in patients with PDAC,
providing the first reported evidence that immunomodulating
therapies may result in dynamic myeloid responses at the
primary tumour, with the potential to limit intended treatment
efficacy. This phenomenon is recapitulated in tumour-bearing
animals, and synergistic targeting of both CXCR2+ TAN and
CCR2+ TAM prevented a compensatory influx of myeloid
cells, along with evidence of a more robust antitumour immune
response. These data build on emerging therapies targeting
bone marrow-derived cells in human cancer and suggests that
targeting both TAM and TAN collectively may represent the
optimal therapeutic combination.
Nywening TM, et al. Gut 2018;67:1112–1123. doi:10.1136/gutjnl-2017-313738

An institutional review board (IRB)-approved, prospectively
maintained database of PDAC resections (n=561) performed at
Barnes Jewish Hospital (St. Louis, Missouri, USA) between 1997
and 2012 was used, and the NLR was calculated by dividing the
absolute neutrophil and lymphocyte values from routine preoperative labs obtained within 30 days prior to the index pancreatectomy. Subjects with leucocytosis (>11 000 cells/dL) (n=51),
without a differential count (n=64) or postoperative death
within 30 days (n=7) were excluded. The NLR, as a continuous
variable, was used as the test state and overall survival as the
control variable in a standard receiver operator curve (ROC) to
determine the optimal cut-off point for patient stratification.

Collection of blood, bone marrow and tumour from human
patients

Human studies were conducted with informed consent under
IRB-approved protocol at Washington University School of
Medicine. Unfractionated whole blood and bone marrow aspirates were collected from patients with PDAC and healthy
controls in EDTA vacuum tubes (BD Bioscience) and underwent red blood cell (RBC) lysis per manufacturer’s instructions
(BioLegend). Resected tumour or normal pancreas from organ
donors without malignancy were processed at time of collection.
Baseline and post-treatment tumour biopsies from a clinical trial
were processed as previously described.19 Tissue was allocated
for cryopreservation, fixation or enzymatically digested to create
a single cell suspension using GentleMACS (Miltenyi).

PDAC tumour tissue microarray (TMA)

A TMA of treatment-naive PDAC tumours was constructed
from 1 mm punch biopsies of well-demarcated tumours from
paraffin-embedded tissue blocks by a pathologist. An Aperio
Scan-Scope XT Slide Scanner (Aperio Technologies) was used
to acquire 20× images. A previously validated tumour-specific
nuclear algorithm (IHC-MARK) was used to quantify protein
expression.14 22 Positive staining was normalised to total tissue
surface area and the mean intensity or cellular density per cm2
was used to classify samples into high, mid and low cohorts and
overall survival following PDAC resection compared (online
supplementary figure S1).

Animal studies and cell lines

C57BL/6, CCR2−/− (B6.129S4-Ccr2tm1Ifc/J) and Nur77GFP
(Nur77-GFPCre) mice were purchased from The Jackson
Laboratory and maintained in a pathogen-free facility under
an approved animal studies protocol at Washington University School of Medicine (St. Louis, Missouri, USA). Mice
were observed daily, and survival events were recorded when
animals lost >15% total body weight or per absolute survival
event. The murine PDAC cell line KCKO was the kind gift of
Dr Pinku Mukherjee.23 KPC cells derived from p48-CRE/
LSL-Kras/p53flox/flox mice were provided by Dr David DeNardo.
All cell lines tested negative for mycoplasma and verified to be
of C57BL/6J origin using CellCheck Plus (IDEXX BioResearch).
Mice aged 8–10 weeks were anaesthetised and injected in the
tail of the pancreas with 2.5×105 cells suspended in a 1:1 PBS
to Matrigel (Corning) mixture and randomised to treatment
96 hours following tumour inoculation. The CXCR2 inhibitor
(CXCR2i) SB225002 (Tocris) was administered intraperitoneally
(IP) at a dose of 10 mg/kg daily. The CCR2i RS504393 (Tocris)
was given subcutaneously (SQ) at a dose of 5 mg/kg twice per
1113
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What is already known on this subject?
►► Bone marrow-derived myeloid cells, including
tumour-associated neutrophils (TAN) and tumourassociated macrophages (TAM) are recruited by pancreatic
adenocarcinoma (PDAC) and facilitate immune evasion.
►► PDAC production of CCL2 promotes CCR2+ monocyte efflux
from the bone marrow to the tumour microenvironment,
where they become immunosuppressive TAM.
►► Treatment with a small molecule CCR2 inhibitor, in
combination with FOLFIRINOX, prevented TAM accumulation
and demonstrated a promising treatment response rate in
PDAC compared with chemotherapy alone.
►► The ELR+/CXCR2 chemokine axis has been implicated in
PDAC-mediated recruitment of TAN, and CXCR2 blockade has
shown promise in preclinical tumour studies.

Materials and methods
Analysis of preoperative neutrophil to lymphocyte ratio (NLR)

Pancreas

Flow cytometry

Single cell suspensions were assessed for viability with Trypan
Blue and manually counted, then incubated with Fc receptor
blocking solution followed by fluorophore-conjugated antibodies (BioLegend). For intracellular staining, cells were
permeabilised and stained with appropriate antibody per
manufacturer’s instructions (eBioscience). Flow cytometry was
performed on an LSRII (BD Biosciences) and analysed using
FloJo Version X (Tree Star). See online supplementary materials for list of antibodies.

RNA isolation and PCR

Snap-frozen samples were homogenised in Trizol (Thermo
Scientific) with a Tissue Lyser LT (Qiagen). Total RNA was
extracted with the RNeasy Mini Kit and treated with DNase
(Qiagen). RNA was reverse transcribed into cDNA and quantitative real-time PCR performed using TaqMan PCR Master
Mix and predesigned TaqMan Gene Expression Assays
(Thermo Scientific). Gene expression was normalised to lyceraldehyde-3-phosphate dehydrogenase (GAPDH), hypoxanthine phosphoribosyltransferase (HPRT1) and β-actin using
the comparative CT (ΔΔCT) method.

Immunofluorescence and immunohistochemistry

Five micrometre tumour sections were cut from embedded
tissue using an HM 325 microtome (Thermo Scientific) and
baked at 70°C for 30 min. Tissue sections were dewaxed in
xylene followed by rehydration and antigen retrieval using
citrate buffer (10 mM sodium citrate, 0.05% Tween 20), then
washed and blocked with serum-free protein block (DAKO).
Primary antibodies were diluted in antibody diluent (DAKO)
and incubated overnight at 4°C then washed and stained with
fluorescently conjugated secondary antibodies diluted 1:200
for 30 min at room temperature. For immunohistochemistry,
endogenous peroxidase activity was blocked by incubation
with 3% H2O2 in PBS, followed by primary and biotinylated
secondary antibodies diluted 1:200. Antigen staining with
VECTASTAIN Standard ABC Kit (Vector Laboratories)
and Liquid DAB+ Substrate Chromagen System (DAKO)
was performed, and slides were counterstained with Gill’s
Hematoxylin (Fisher Scientific). Images were acquired on an
Olympus BX43 microscope with a DP80 camera and analysed
with manufacture’s software (Olympus).

Statistical analysis

SAS V.9.1 and GraphPad Prism V.4 (GraphPad Software) were
used for statistical analysis using a significance level of α=0.05.
A two-sided Student’s t-test or Mann-Whitney test was used
for normally and non-Gaussian distributed data, respectively.
Matched samples were compared with a two-sided paired t-test.
A one-way analysis of variance using the Tukey post-test was
used for multiple comparisons. Survival analysis was performed
using the log-rank test.
1114

Results
Preoperative NLR correlates with survival following PDAC
resection

Using standard ROC analysis the optimal NLR cut-off was determined to be 2.1, with patients (n=439) stratified into high (>2.1)
and low (≤2.1) cohorts. Overall, a high NLR (n=286) was
associated with a worse prognosis and 5-year survival of 17.3%
compared with 26.5% in the low NLR group (n=153) following
PDAC resection (figure 1A). Patients with a high NLR had a median
survival of 18 months compared with 23 months in the low NLR
group (HR=0.74 (95% CI 0.58 to 0.93)). Multiple logistic regression using baseline patient and tumour characteristics reveals that
an elevated preoperative NLR is independently associated with a
shorter mean survival (online supplementary table S1).

Neutrophils expressing CXCR2 are elevated in the blood and
bone marrow of patients with human PDAC

Flow cytometry analysis reveals that neutrophils in both the blood
and bone marrow express CXCR2 (figure 1B). Patients with
PDAC demonstrated a significant increase in CXCR2+ neutrophils in the blood compared with healthy controls (figure 1C).
The circulating CXCR2+ neutrophil burden was higher in patients
surviving less than 1 year and inversely correlated with survival
(P=0.019; Pearson’s rho=−0.66 (95% CI −0.90 to −0.14)).
Likewise, patients with PDAC had increased CXCR2+ neutrophils in bone marrow compared with controls (figure 1D). Similar
to the peripheral blood, this increase was associated with worse
1-year survival and the percentage of bone marrow CXCR2+
neutrophils inversely correlated with survival (P=0.014; Pearson’s rho=−0.50 (95% CI −0.76 to −0.11)). This indicates that
PDAC results in a systemic elevation of CXCR2+ neutrophils
in the blood and bone marrow, correlating with worse clinical
outcomes.

Increased expression of ELR+ chemokines correlates with the
prevalence of tumour-infiltrating CXCR2+ TAN

Consistent with prior reports, we found that human PDAC
tumours overexpress GM-CSF and G-CSF, but not M-CSF, relative
to normal pancreas (figure 2A).24 25 PDAC tumours had increased
expression of the ELR+ chemokines CXCL1, CXCL2, CXCL5
and CXCL8 compared with normal tissue (figure 2B). Fluorescent microscopy shows neoplastic ductal cells, rather than stromal
elements, to be the primary source of CXCL1, CXCL2, CXCL5
and CXCL8 (figure 2C). In particular, we focused on CXCL5 as it
demonstrated the greatest fold increase in PDAC expression among
the ELR+ chemokines and found a positive correlation between
CXCL5 expression and both tumour-infiltrating CD15+ granulocytes (Pearson rho=0.837 (95% CI 0.73 to 0.90); figure 2D)
and neutrophil elastase positive (NE+) granulocytes (Pearson
rho=0.635 (95% CI 0.43 to 0.70); figure 2E). Overall, this
suggests that PDAC expression of ELR+ chemokines, in particular
CXCL5, may be important in facilitating recruitment of CXCR2+
neutrophils.

PDAC tumours are infiltrated by CXCR2+ TAN with prognostic
implications in human disease

Compared with normal pancreas, PDAC is heavily infiltrated by CXCR2+ TAN (figure 2F). Similar to our finding
that the NLR was prognostic in the peripheral blood, we
found PDAC tumours with a low, mid or high CD15+ TAN
to CD8+ lymphocyte ratio had median survival of 2, 1.5
and 1 years, respectively (figure 2G). A high ratio was associated with worse overall survival compared with both the
Nywening TM, et al. Gut 2018;67:1112–1123. doi:10.1136/gutjnl-2017-313738
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day or PF-04136309 (Pfizer) at a dose of 100 mg/kg given SQ
twice daily. FOLFIRINOX (5-FU (25 mg/kg), irinotecan (50 mg/
kg) and oxaliplatin (5 mg/kg)) was administered intravenously
weekly. For depletion experiments, 250 µg of Ly6G (A18) or
CD8 (2.43) antibodies was administered IP every 4 days (BioXCell). Treatment was continued until designated time points, at
which time mice were euthanised and perfused. Tumours were
collected along with blood and bone marrow in heparinised
capillary tubes followed by RBC lysis (BioLegend).
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Figure 1 Systemic elevation of CXCR2+ neutrophils in the peripheral blood and bone marrow correlates with overall survival in patients with human
PDAC. (A) Standard ROC analysis (P<0.0001; AUC=0.74 (95% CI 0.71 to 0.78)) was used to ascertain the preoperative neutrophil to lymphocyte
ratio (NLR) optimal cut-off point of 2.1 with a sensitivity of 66.2% (95% CI 61.2 to 70.6) and specificity of 73.2% (95% CI 68.9 to 77.3). All patients
(n=439) were stratified into high (>2.1; n=286) and low (≤2.1; n=153) cohorts and a Kaplan-Meier survival analysis following PDAC resection was
performed, with alive patients censored at date of last follow-up. (B) Representative flow cytometry plots gated on CD45+ cells depicting CD15+,
CXCR2+ neutrophils in the peripheral blood (top) and bone marrow (bottom) from healthy controls (left) and patients with PDAC (right). (C) Analysis
of CXCR2+ neutrophils in the peripheral blood of healthy controls (n=6) and patients with PDAC (n=17) represented as a percentage of total cells
(left). Comparison of CXCR2+ neutrophils in the peripheral blood of patients with human PDAC surviving (n=11) or deceased (n=6) at 1 year following
surgical resection (middle). Pearson correlation (two tailed) of peripheral blood CXCR2+ neutrophils and survival following surgical resection (right).
(D) Analysis of CXCR2+ neutrophils in the bone marrow of healthy controls (n=5) and patients PDAC (n=24) represented as a percentage of total
cells (left). Comparison of CXCR2+ neutrophils in the bone marrow of patients with human PDAC surviving (n=18) or deceased (n=6) at 1 year
following surgical resection (middle). Pearson correlation (two tailed) of bone marrow CXCR2+ neutrophils and survival following surgical resections
(right). Two-sided Mann-Whitney test was used to determine P values for comparisons between groups. AUC, area under the curve; PDAC, pancreatic
adenocarcinoma; ROC, receiver operator curve.
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Figure 2 Elevated ELR+ chemokine expression correlates with CXCR2+TAN and worse prognosis in human PDAC. (A) Quantitative real-time PCR
analysis of GM-CSF, M-CSF and G-CSF expression from human PDAC tumours (n=11) relative to normal pancreas (n=7). (B) Quantitative real-time
PCR analysis of the ELR+ chemokine CXCL1, CXCL2, CXCL5 and CXCL8 expression from human PDAC tumours (n=11) relative to normal pancreas
(n=7). (C) Fluorescent microscopy images demonstrating CXCL1, CXCL2, CXCL5 and CXCL8 (red) expression with DAPI nuclear (blue) and cytokeratin
7 (CK7; green) counterstain in human PDAC tumours. (D) Pearson (two tailed) correlation of CXCL5 expression intensity and CD15+ TAN infiltrate
in human PDAC tumours (n=54). (E) Pearson correlation (two tailed) of CXCL5 expression intensity and NE+ TAN infiltrate in human PDAC tumours
(n=54). (F) Representative immunofluorescence showing CD11b+, CD15+ TAN (yellow) in normal pancreas (top) and PDAC tumours (bottom).
Representative flow cytometry plots illustrating CD11b+, CD15+, CD66b+, CXCR2+ TAN in normal pancreas (top) and PDAC tumour (bottom) gated
on CD45+ cells. Graph depicts CXCR2+ TAN as percentage of total cells by flow cytometry from normal pancreas (n=7) and human PDAC tumours
(n=11). (G) Survival analysis of intratumoural CD15+ to CD8+ ratio from resected human PDAC tumour microarray (n=49). (H) Survival analysis of
intratumoural NE+ to CD8+ ratio from resected human PDAC tissue microarray (n=49). (I) Survival analysis of intratumoural CXCL5 to CD8+ ratio
from resected human PDAC tissue microarray (n=49). Two-tailed unpaired t-test or Kaplan-Meier survival analysis was used to calculate P values.
*P<0.05; **P<0.01; ***P<0.001. G-CSF, granulocyte colony-stimulating factor; GM-CSF, granulocyte-macrophage colony-stimulating factor; M-CSF,
macrophage colony-stimulating factor; PDAC, pancreatic adenocarcinoma; TAN, tumour-associated neutrophils.
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CXCR2 inhibition sequesters neutrophils in the blood and
prevents TAN accumulation in orthotopic PDAC tumours

Orthotopically implanted, syngenic KCKO pancreatic tumours
demonstrated increased expression of GM-CSF, G-CSF and the
CXCR2 ligands CXCL1, CXCL2 and CXCL5 relative to normal
pancreas (figure 3A and figure 3B). In addition, we found a systemic
elevation of CXCR2+ neutrophils in the bone marrow and peripheral blood of tumour-bearing mice relative to controls (figure 3C).
CXCR2i treatment increased the absolute number of neutrophils
in the periphery, but not the bone marrow, compared with vehicle
treated animals. In addition, we explored the impact of FOLFIRINOX, which also demonstrated an increase in circulating, but
not bone marrow, granulocytes following CXCR2i plus myelosuppressive chemotherapy (online supplementary figure S2).
The primary tumour was characterised by an abundant
infiltrate of polynuclear Ly6G+ cells, which was abrogated
with CXCR2 inhibition (figure 3D). Targeting CXCR2+ TAN
resulted in a significant reduction in subcutaneous KCKO
tumour progression (figure 3E). To confirm these findings, we
examined orthotopic tumours from another syngenic PDAC cell
line derived from the KPC genetically engineered model (p48CRE/LSL-KrasG12D/p53flox/flox), revealing CXCR2i also prevented
TAN accumulation in this model (online supplementary figure
S3). Furthermore, treatment with either CXCR2i or a Ly6G-specific depleting antibody (A18) demonstrated a similar reduction
in established KPC disease burden compared with controls
(figure 3F). Collectively, this suggests that CXCR2 blockade
prevents neutrophil trafficking from the blood, reducing TAN
with similar therapeutic efficacy to systemic depletion.

Targeting a myeloid subset results in tumour compensatory
recruitment of alternative bone marrow-derived cell
populations

Neutrophil substitution for CCR2+ TAM has been observed
in tumour models, and targeting CCR2 has shown promising
results in a clinical trial treating borderline resectable and locally
advanced PDAC.19–21 Thus, we examined if CXCR2+ TAN
compensation occurred in human patients by analysing baseline and post-treatment tumour biopsies following 4 weeks of
treatment with CCR2i, which revealed a significant increase
in CXCR2+ TAN following CCR2 blockade (figure 4A). Both
tumour-bearing CCR2−/− and CCR2i-treated wild-type mice
demonstrated a compensatory replacement of TAM by CXCR2+
granulocytes, which also occurred when treated in combination with FOLFIRINOX (figure 4B,C). Conversely, depletion
of Ly6G+ neutrophils has been reported to result in elevated
TAM in a spontaneous PDAC murine model, which is similar
Nywening TM, et al. Gut 2018;67:1112–1123. doi:10.1136/gutjnl-2017-313738

to our findings following CXCR2i treatment (figure 4C,D)
(figure 4D).12 One possible explanation for this phenomenon
is the observation that factors associated with TAM production and recruitment, namely CSF1 and CCL2, were increased
following blockade of CXCR2+ TAN. Similarly, CCR2i resulted
in an increased expression of CXCL1, CXCL2 and CXLC5 as
well as G-CSF (online supplementary figure S4). Nonetheless,
combined CCR2i plus CXCR2i treatment, both alone and in
combination with FOLFIRINOX, prevented this compensatory
effect and reduced tumour-infiltrating myeloid cells (figure 4E).

Combined CCR2 plus CXCR2 blockade enhances
chemotherapeutic efficacy and improves survival in tumourbearing mice

While CCR2i and CXCR2i were effective at reducing established
orthotopic tumour burden as single agents, using a dual CCR2
plus CXCR2 blockade strategy resulted in significantly smaller
KCKO tumours (figure 4F). Furthermore, this reduction in tumour
burden was enhanced when myeloid blockade was combined with
FOLFIRINOX. Administration of PF-04136309, a small molecule CCR2i used in a human PDAC clinical trial, in combination
with FOLFIRINOX, reveals that chemotherapy increased survival
compared with vehicle treatment (P<0.001; median survival: 15
vs 19 days), but the addition of either CCR2i (P=0.013; median
survival: 19 vs 25 days) or CXCR2i (P=0.013; median survival:
19 vs 24 days) further improved survival in mice with orthotopic
tumours derived from the KPC genetically engineered model
(figure 4G). Furthermore, dual CCR2 plus CXCR2 blockade with
FOLFIRINOX increased survival compared with either CCR2i
(P=0.016; median survival: 25 vs 33 days) or CXCR2i (P=0.015;
median survival: 24 vs 33 days). Overall, this suggests that
targeting myeloid cell recruitment with both CCR2 and CXCR2
simultaneously enhances chemotherapeutic responses compared
with either strategy used alone.

Reduction of tumour-infiltrating myeloids increases effector
T cells in PDAC-bearing mice

Targeting CCR2+ TAM and CXCR2+ TAN in combination
resulted in a significantly greater influx of both CD8+ and CD4+
TIL compared with either strategy alone, which was also found
when tested in combination with FOLFIRINOX (figure 5A,B).
Examination of TIL subsets found that myeloid-targeting strategies decreased immunosuppressive FoxP3+ and CD25+ regulatory T cell infiltrate, with no further clear benefit found when
CCR2i and CXCR2i were combined (figure 5C). Confirming
our prior findings, fluorescent microscopy shows that CD8+ TIL
are increased following myeloid blockade (online supplementary figure S5). Next, we assessed markers of CD8+ TIL activation status, which revealed an increase in intracellular IFNγ
and CD44+, CD69+, CD62L− surface marker expression on
CD8+ TIL following combined CCR2i plus CXCR2i treatment
(figure 5D,E). To confirm that this increase in activation status
faithfully reflected antigen recognition by the T cell receptor
(TCR), we next examined the green fluorescent protein (GFP)
expression in CD8+ lymphocytes extracted from PDAC tumours
in Nur77GFP reporter mice, which upregulate GFP in response
to TCR stimulation.26 27 This demonstrated an increase in GFP
expressing CD8+ TIL following dual CCR2i plus CXCR2i
treatment (figure 5F). Overall, these results indicate that the
corresponding reduction of tumour-infiltrating myeloid cells
and influx of effector TIL following dual chemokine receptor
inhibition may represent the ideal treatment strategy to augment
chemotherapeutic responses in PDAC.
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mid (P=0.009; HR=0.44 (95% CI 0.14 to 0.76)) and low
(P=0.006; HR=0.35 (95% CI 0.12 to 0.70)) groups. Furthermore, PDAC patients with a high NE to CD8 intratumoural
ratio demonstrated decreased survival compared with those in
either the mid (P=0.008; HR=0.35 (95% CI 0.07 to 0.51))
or high (P=0.006; HR=0.34 (95% CI 0.10 to 0.68)) cohorts
(figure 2H). Consistent with our finding that CXCL5 expression correlated with TAN infiltrate, an elevated CXCL5 to
CD8+ intratumoural ratio was also associated with a worse
prognosis, with a median survival of 0.65 years compared with
the 1.3 years (P=0.019; HR=0.39 (95% CI 0.05 to 0.75))
or 1.8 years (p=0.005; HR=0.47 (95% CI 0.03 to 0.51))
observed in the mid and low groups, respectively (figure 2I). In
summary, this suggests that the CXCR2+ TAN are a predominant immune infiltrate and have clinical significance in PDAC.
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Figure 3 Targeting CXCR2 sequesters neutrophils in the peripheral blood and prevents TAN accumulation in PDAC tumour-bearing animals. (A)
Quantitative real-time PCR was performed for expression of GM-CSF, M-CSF and G-CSF on normal murine pancreas (n=5) and orthotopically
implanted KCKO PDAC tumours (n=9). (B) Quantitative real-time PCR was performed for expression of ƩCXC+ chemokines on normal murine
pancreas (n=5) and orthotopically implanted PDAC tumours (n=9). (C) Representative flow cytometry plots of CXCR2+ neutrophils in the peripheral
blood (top) and bone marrow (bottom) from non-tumour controls and tumour-bearing animals receiving treatment with vehicle or CXCR2i.
Graphs depict absolute number of CXCR2+ neutrophils (×105) per 100 µL of blood (n=9–12 per group) and bone marrow from the femur (n=4 per
group) of non-tumour-bearing controls and KCKO tumour-bearing animals receiving treatment with vehicle or CXCR2i (D) Representative IHC and
analysis of Ly6G+ TAN from orthotopic PDAC tumours of animals treated with vehicle or CXCR2i (n=6–9 per group). (E) Tumour growth curve of
subcutaneously implanted KCKO tumours from mice treated with vehicle or CXCR2i. Treatment initiated following randomisation of palpable tumours
on postimplantation day 10. (F) Tumour weights from established orthotopic KPC tumours treated with CXCR2i or Ly6G specific depleting antibody
for 20 days (n=6 per group). Data reflect analysis from at least two repeated experiments. Two-tailed unpaired t-test or ANOVA was used to calculate
P values. *P<0.05; **P<0.01; ***P<0.001. ANOVA, analysis of variance; PDAC, pancreatic adenocarcinoma; TAN, tumour-associated neutrophils.
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Figure 4 Human and murine PDAC tumours demonstrate myeloid substitution following bone marrow cell targeted therapies, which is overcome
by combined CCR2 plus CXCR2 blockade. (A) Comparison total PDAC-infiltrating CXCR2+ TAN was assessed by flow cytometry from matched FNA
tumour biopsies at baseline following treatment with an orally dosed, small molecule CCR2i (blue) in combination with FOLFIRINOX (n=6 matched
specimens). (B) Absolute number of CXCR2+ TAN per gram of tissue (×105) was assessed by flow cytometry from CCR2−/− and wild-type mice
treated with vehicle alone (left) or in combination with FOLFIRINOX (right) 25 days following orthotopic KCKO tumour implantation (n=5–6 mice/
group). (C) Absolute number of CXCR2+ TAN (Left) and CCR2+ TAM (Right) per gram of tumour (×105) was assessed by flow cytometry following
25 days of treatment with chemokine blockade alone (n=12 mice/group) . (D) Absolute number of CXCR2+ TAN (Right) and CCR2+ TAM (Left) per
gram of tumour (×105) was assessed by flow cytometry following 25 days of treatment with chemokine blockade in combination with FOLFIRINOX
chemotherapy (n=9 mice/group). (E) Total tumour-infiltrating myeloids was assessed by flow cytometry and represented as percentage change from
vehicle treated controls following chemokine receptor blockade alone and in combination with FOLFIRINOX (n=9–12 mice/group). (F) Orthotopic
KCKO tumour weights following 25 days of treatment with chemokine receptor blockade alone (left; n=12 mice/group) and in combination with
FOLFIRINOX chemotherapy (right; n=9 mice/group). (G) Survival analysis of KPC orthotopic tumour-bearing mice treated with FOLFIRINOX alone and
in combination with PF-04136309 (CCR2i) or CXCR2i (n=10–15 mice per group). One-way ANOVA and two-tailed paired, for matched samples, or
unpaired t-test were used to calculate P values. For survival analysis, P values were obtained by the log-rank (Mantel-Cox) test. *P<0.05; **P<0.01;
***P<0.001. ANOVA, analysis of variance; PDAC, pancreatic adenocarcinoma; TAM, tumour-associated macrophages; TAN, tumour-associated
neutrophils.
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Dual CCR2 plus CXCR2 blockade restores antitumour
immunity in established PDAC tumours

The effector to suppressor cell ratio in established, orthotopically
implanted PDAC tumours was increased following treatment with
either CCR2i or CXCR2i compared with controls (figure 5G).
Nonetheless, simultaneous targeting of both CCR2+ TAM and
CXCR2+ TAN further enhanced this effect, which was magnified
1120

when combined with FOLFIRINOX. This corresponded with
reduced expression of immunosuppressive genes and increase in
factors associated with antitumour immunity and cytolytic T cell
responses (figure 5H). As our results suggest that antitumour
activity following myeloid blockade is mediated through an adaptive immune mechanism, we performed CD8 depletion studies that
showed the therapeutic efficacy of myeloid blockade is lost in the
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Figure 5 Depleting PDAC-infiltrating CCR2+ macrophages and CXCR2+ neutrophils in combination improves antitumour T cell responses. (A)
Absolute number of CD8+ TIL per gram of tumour (×105) was assessed by flow cytometry from orthotopically implanted KCKO tumours following
25 days of treatment with chemokine blockade alone (left; n=12 mice/group) and in combination with FOLFIRINOX chemotherapy (right; n=9 mice/
group). (B) Absolute number of CD4+ TIL per gram of tumour (×105) was assessed by flow cytometry from orthotopically implanted KCKO tumours
following 25 days of treatment with chemokine blockade alone (left; n=12 mice/group) and in combination with FOLFIRINOX chemotherapy
(right; n=9 mice/group). (C) Regulatory T cells (FoxP3+ and CD25+) expressed as percentage of total CD4+ TIL was assessed by flow cytometry
from orthotopically implanted KCKO tumours following 25 days of treatment with chemokine blockade alone (left; n=9–12 mice/group) and in
combination with FOLFIRINOX chemotherapy (right; n=6 mice/group). (D) Intracellular IFNγ-positive CD8+ TIL expressed as percentage of total CD8+
T cells was assessed by flow cytometry from orthotopically implanted KCKO tumours following 25 days of treatment with chemokine blockade alone
(left; n=6 mice/group) and in combination with FOLFIRINOX chemotherapy (right; n=6 mice/group). (E) CD69+, CD44+, CD62L−and activated CD8+
TIL expressed as percentage of total CD8+ TIL were assessed by flow cytometry from orthotopically implanted KCKO tumours following 25 days of
treatment with chemokine blockade alone (left; n=9 mice/group) and in combination with FOLFIRINOX chemotherapy (right; n=6 mice/group). (F) GFP
expressing CD8+ TIL assessed by flow cytometry from Nur77GFP T cell report mice with KCKO tumours 21 days following treatment with chemokine
receptor inhibitor (n=4–6 mice/group). (G) Intratumoural effector to suppressor cell ratio per gram of tumour from orthotopically implanted
KCKO tumours following 25 days of treatment with chemokine blockade alone (left; n=9–12 mice/group) and in combination with FOLFIRINOX
chemotherapy (right; n=9 mice/group). (H) Orthotopic KCKO tumour gene expression following 25 days of treatment with chemokine blockade alone
(left; n=5 mice/group) and in combination with FOLFIRINOX chemotherapy (right; n=5 mice/group). (I) Orthotopic KCKO tumour weights following
chemokine receptor inhibitor with CD8 depleting antibody or IgG control (n=5–6 mice/group). One-way ANOVA was used to calculate P values.
*P<0.05; **P<0.01; ***P<0.001. ANOVA, analysis of variance; PDAC, pancreatic adenocarcinoma; TIL, tumour- infiltrating lymphocytes.
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Discussion

Herein we demonstrate that myeloid dynamics within the TME
facilitates a compensatory increase in an alternative subset of bone
marrow-derived cells following isolated depletion of either CCR2+
TAM or CXCR2+ TAN. Furthermore, we provide the first evidence
of this phenomenon occurring in human cancer, with post-treatment
tumour biopsies from patients with non-metastatic PDAC receiving
a small molecule CCR2i plus FOLFIRINOX demonstrating a
significant increase in TAN compared with matched baseline
samples. This increase may have clinical implications as we found
that CXCR2+ neutrophils are elevated in the blood, bone marrow
and tumour of patients with human PDAC and correlates with poor
overall survival. Likewise, tumour-bearing mice demonstrate an
increase in CXCR2+ neutrophils following therapeutic targeting of
CCR2+ TAM. Conversely, we also show that preventing CXCR2+
neutrophil mobilisation in PDAC results in an increase in TAM,
and synergistic targeting of both CXCR2+ TAN and CCR2+ TAM
improves antitumour immunity and reduces established tumour
burden compared with either therapy alone. In summary, these
data build on emerging therapies targeting myeloid cells in human
cancer and suggests that targeting both TAN and TAM collectively
may present the optimal therapeutic combination in combating the
immunosuppressive microenvironment.
An emerging body of evidence supports the role of TAN in
facilitating tumour immune evasion and progression.28 Patients
with cancer demonstrate a systemic increase in neutrophils, and
the NLR is a biomarker in several tumours, including PDAC, and
elevated neutrophils in the circulation correlated with tumour-infiltrating TAN in patients with glioblastoma.29–33 Recruitment of
CXCR2+ neutrophils via tumour production of ELR+ chemokines has been observed in multiple cancers, with CXCL5
correlating with increased TAN infiltrate and worse prognosis
in hepatocellular carcinoma and PDAC.8 9 34 Orally dosed small
molecule inhibitors of CXCR2 are currently in clinical development, with trials demonstrating evidence of target engagement
and a favourable toxicity profile in non-malignant conditions, and
targeting CXCR2+ TAN has demonstrated efficacy in preclinical tumour models.35 36 Jamieson et al found CXCR2 blockade
prevented TAN migration to colorectal tumours and increased
CD8+ effector TIL, reducing tumour progression. In rhabdomyosarcoma, Highfill et al found that CXCR2 blockade potentiated
anti-PD1 immunotherapy in tumour-bearing mice.10 13 In pancreatic cancer, Stromnes et al12 reported that TAN depletion with a
Ly6G-specific antibody leads to enhanced CD8+ TIL influx and
an increase in cancer cell apoptosis in KPC mice. Likewise, strategies using CXCR2 blockade have also been associated with an
influx of TIL and augmented checkpoint therapy in PDAC.9 11
Collectively, both our work and that of others strongly suggests
that targeting CXCR2-mediated mobilisation of neutrophils may
present a promising therapy for cancer.
Immunosuppressive TAM are also abundant in cancer and
correlate with poor prognosis.37 Strategies targeting TAM, including
CCR2 and CSF1 receptor blockade, repolarise the immunosuppressive microenvironment, improve responses to chemotherapy
and reduce metastasis in preclinical models.14 16–18 38 The translation of these therapies to the clinic has also demonstrated promise
with our group previously reporting that PF-04136309, an orally
dosed CCR2i, in combination with FOLFIRINOX, demonstrated
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a favourable clinical response rate compared with chemotherapy
alone in patients with borderline resectable and locally advanced
PDAC.19 Correlative studies from this clinical trial showed CCR2i
reduced TAM and increased TIL, suggesting that CCR2 blockade
favourably reprogrammes the immunosuppressive TME. Based on
these findings, larger clinical trials exploring CCR2 blockade in
metastatic PDAC in combination with gemcitabine plus nab-paclitaxel (NCT02732938) and FOLFIRINOX (NCT02345408) are
currently in progress. Likewise, strategies targeting CSF1 receptor
have shown evidence of TAM reduction and promising response
rates in patients with tenosynovial giant cell tumours, suggesting
such strategies may be beneficial in the treatment of a variety of
human cancers.39 40
While TAM targeted therapeutics have demonstrated evidence
of safety and tolerability in cancer, inhibition of neutrophil
recruitment has been met with more resistance, particularly
in combination with chemotherapy regimens associated with
myelosuppression and neutropaenia. Yet, systemic neutrophilia
correlates with poor clinical outcomes in cancer, with evidence
that chemotherapy-induced neutropaenia is protective in multiple
solid tumours.41–43 Furthermore, elevated neutrophils have been
associated with resistance to conventional therapies.44 45 Kurihara et al46 reported similar findings in advanced PDAC, where
neutropaenia conveyed a survival benefit following gemcitabine
treatment. Importantly, a study in ovarian cancer found the baseline neutrophil count to correlate with survival, but carboplatin
dose-escalation based on nadir neutrophil counts did not improve
clinical outcomes, suggesting that chemotherapy does not overcome tumour-mediated granulocyte expansion.47 We used the
FOLFIRINOX regimen in this study as it has shown an improvement in survival in PDAC compared with gemcitabine but is associated with an increase in treatment-related toxicities, including
neutropaenia.48 Our results indicate that conventional chemotherapy does not sufficiently target TAN and suggests that CXCR2
inhibition may represent a synergistic treatment combination.
Despite successes targeting a single myeloid subset, the
dynamics of bone marrow-derived cell recruitment in response to
such immunomodulatory strategies has not been fully evaluated.
Sawanobori et al21 revealed that CCR2−/− mice had an influx of
tumour-infiltrating neutrophils in both Lewis lung carcinoma and
B16 melanoma tumours. Pahler et al20 have reported similar findings in cervical cancers from CCR2−/− mice, in which the neutrophil influx was responsible for treatment resistance. Neutrophil
substitution for macrophages has also been reported to other sites
of inflammation in CCR2−/− mice infected with Listeria monocytogenes or viral-induced arthritis.49 50 Conversely, there is evidence
that neutrophil depletion results in a compensatory increase in
TAM. Stromnes et al showed that targeted depletion of neutrophils
resulted in a systemic accumulation of myelomonocytic cells in
both the periphery and tumour in a genetically engineered model
of PDAC, suggesting that tumour-infiltrating myeloid compensation may occur following therapies targeting TAN as well.12
Collectively, these findings demonstrate both the critical nature of
tumour-mediated recruitment of bone marrow-derived cells and
support the concept of tumour-infiltrating myeloid substitution
to counteract therapeutic strategies targeting an isolated myeloid
cell population. Thus, further understanding of the mechanisms
behind this phenomenon and how it may contribute to treatment
resistance is paramount in the clinical application of targeting
myeloid cells in cancer.
The dynamic communication between the tumour and bone
marrow demonstrates the importance of precisely defining
the immune composition of the TME and recognition of
the potential mechanisms that tumours may use to combat
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absence of CD8+ lymphocytes (figure 5I). In summary, these data
highlight the critical importance of bone marrow-derived cells in
mediating PDAC immune evasion and provides a clinical rationale
for concurrent targeting of both CCR2+ TAM and CXCR2+ TAN.

Pancreas

Author affiliations
1
Department of Surgery, Washington University School of Medicine, St. Louis,
Missouri, USA
2
Alvin J Siteman Cancer Center, Washington University School of Medicine, St Louis,
Missouri, USA
3
Department of Surgery, University of Rochester Medical Center, Rochester, New
York, USA
4
Tumor Biology Program, University of Rochester Medical Center, Rochester, New
York, USA
5
Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, New
York, USA
6
Department of Medicine, Oncology Division, Washington University School of
Medicine, St. Louis, Missouri, USA
7
Department of Pathology & Immunology, Washington University School of Medicine,
St. Louis, Missouri, USA
Acknowledgements The authors would first and foremost like to express their
appreciation to the patients who participated for contributing to further the scientific
understanding of this devastating disease. The authors would like to personally thank
Lori Worley and Dr Steven M Strasberg for assistance with specimen collection as
well as Dr Daniel Kreisel and Dr Timothy Fleming for providing editorial feedback on
the manuscript. The small molecule CCR2 inhibitor PF-04136309 was generously
supplied by Pfizer.
Contributors TMN, BAB, SPG and DCL designed the study. TMN, BAB, DRC, RZP,
BJH, DES, RCJ, JY and AAP performed experiments and conducted analysis. RCF,
WGH and DCL assisted in operative specimen collection. RCF, WEG, DGD, WGH and
DCL provided funding support, assistance with experimental design and edited the
manuscript. TMN wrote the manuscript with input from all authors.
Funding TMN, DRC, RZP and DES recognise support from the NIH T32 CA 009621
training grant in Surgical Oncology (awarded to WEG). BAB, BJH, JY, AAP and DCL
acknowledge funding from the NIH 5R01CA168863 and the Pancreatic Cancer
Action Network (PANCAN) Translational ResearchGrant (15-65-25 LINE). TMN, DRC,
SPG and WGH also recognise support from the Pancreatic Action Network (16-65Hawk) Translational Research Grant (16-65-Hawk). TMN, DRC, RCF, DGD, SPG and
WGH recognise support from the Siteman Cancer Center Frontier Fund. TMN, BAB,
DRC, WEG, DGD, DCL and WGH recognise funding from the NCI/NIH Specialized
Programs of Research Excellence (SPORE) grant (1P50CA196510). Work supported
in part by a research grant to DCL through the Pfizer/Washington University School
of Medicine Biomedical Collaborative.
Competing interests None declared.
Ethics approval IRB.
Provenance and peer review Not commissioned; externally peer reviewed.
Open Access This is an Open Access article distributed in accordance with the
Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which
permits others to distribute, remix, adapt, build upon this work non-commercially,
and license their derivative works on different terms, provided the original work
is properly cited and the use is non-commercial. See: http://creativecommons.org/
licenses/by-nc/4 .0/
© Article author(s) (or their employer(s) unless otherwise stated in the text of the
article) 2018. All rights reserved. No commercial use is permitted unless otherwise
expressly granted.

References

1 Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin 2017;67:7–30.
2	Rahib L, Smith BD, Aizenberg R, et al. Projecting cancer incidence and deaths to 2030:
the unexpected burden of thyroid, liver, and pancreas cancers in the United States.
Cancer Res 2014;74:2913–21.
3	Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid
cells by tumours. Nat Rev Immunol 2012;12:253–68.
4	Clark CE, Hingorani SR, Mick R, et al. Dynamics of the immune reaction to pancreatic
cancer from inception to invasion. Cancer Res 2007;67:9518–27.
5 Shen M, Hu P, Donskov F, et al. Tumor-associated neutrophils as a new
prognostic factor in cancer: a systematic review and meta-analysis. PLoS One 2014;9:e98259.

1122

6 Donskov F. Immunomonitoring and prognostic relevance of neutrophils in clinical
trials. Semin Cancer Biol 2013;23:200–7.
7	Eash KJ, Greenbaum AM, Gopalan PK, et al. CXCR2 and CXCR4 antagonistically regulate
neutrophil trafficking from murine bone marrow. J Clin Invest 2010;120:2423–31.
8 Zhou SL, Dai Z, Zhou ZJ, et al. Overexpression of CXCL5 mediates neutrophil infiltration
and indicates poor prognosis for hepatocellular carcinoma. Hepatology 2012;56:2242–54.
9	Chao T, Furth EE, Vonderheide RH. CXCR2-dependent accumulation of tumorassociated neutrophils regulates t-cell immunity in pancreatic ductal adenocarcinoma.
Cancer Immunol Res 2016;4:968–82.
10 Highfill SL, Cui Y, Giles AJ, et al. Disruption of CXCR2-mediated MDSC tumor
trafficking enhances anti-PD1 efficacy. Sci Transl Med 2014;6:237ra67.
11 Steele CW, Karim SA, Leach JDG, et al. CXCR2 inhibition profoundly suppresses
metastases and augments immunotherapy in pancreatic ductal adenocarcinoma.
Cancer Cell 2016;29:832–45.
12 Stromnes IM, Brockenbrough JS, Izeradjene K, et al. Targeted depletion of an MDSC
subset unmasks pancreatic ductal adenocarcinoma to adaptive immunity. Gut
2014;63:1769–81.
13 Jamieson T, Clarke M, Steele CW, et al. Inhibition of CXCR2 profoundly
suppresses inflammation-driven and spontaneous tumorigenesis. J Clin Invest
2012;122:3127–44.
14 Sanford DE, Belt BA, Panni RZ, et al. Inflammatory monocyte mobilization decreases
patient survival in pancreatic cancer: a role for targeting the CCL2/CCR2 axis. Clin
Cancer Res 2013;19:3404–15.
15 Zhang QW, Liu L, Gong CY, et al. Prognostic significance of tumor-associated
macrophages in solid tumor: a meta-analysis of the literature. PLoS One 2012;7:e50946.
16 Mitchem JB, Brennan DJ, Knolhoff BL, et al. Targeting tumor-infiltrating macrophages
decreases tumor-initiating cells, relieves immunosuppression, and improves
chemotherapeutic responses. Cancer Res 2013;73:1128–41.
17 Qian BZ, Li J, Zhang H, et al. CCL2 recruits inflammatory monocytes to facilitate
breast-tumour metastasis. Nature 2011;475:222–5.
18 Zhao L, Lim SY, Gordon-Weeks AN, et al. Recruitment of a myeloid cell subset (CD11b/
Gr1 mid) via CCL2/CCR2 promotes the development of colorectal cancer liver
metastasis. Hepatology 2013;57:829–39.
19	Nywening TM, Wang-Gillam A, Sanford DE, et al. Targeting tumour-associated
macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients
with borderline resectable and locally advanced pancreatic cancer: a singlecentre, open-label, dose-finding, non-randomised, phase 1b trial. Lancet Oncol
2016;17:651–62.
20 Pahler JC, Tazzyman S, Erez N, et al. Plasticity in tumor-promoting inflammation:
impairment of macrophage recruitment evokes a compensatory neutrophil response.
Neoplasia 2008;10:329–40.
21 Sawanobori Y, Ueha S, Kurachi M, et al. Chemokine-mediated rapid turnover of
myeloid-derived suppressor cells in tumor-bearing mice. Blood 2008;111:5457–66.
22 Zhu Y, Knolhoff BL, Meyer MA, et al. CSF1/CSF1R blockade reprograms tumorinfiltrating macrophages and improves response to T-cell checkpoint immunotherapy
in pancreatic cancer models. Cancer Res 2014;74:5057–69.
23 Besmer DM, Curry JM, Roy LD, et al. Pancreatic ductal adenocarcinoma mice lacking
mucin 1 have a profound defect in tumor growth and metastasis. Cancer Res
2011;71:4432–42.
24 Pylayeva-Gupta Y, Lee KE, Hajdu CH, et al. Oncogenic Kras-induced GM-CSF production
promotes the development of pancreatic neoplasia. Cancer Cell 2012;21:836–47.
25 Bayne LJ, Beatty GL, Jhala N, et al. Tumor-derived granulocyte-macrophage colonystimulating factor regulates myeloid inflammation and T cell immunity in pancreatic
cancer. Cancer Cell 2012;21:822–35.
26 Moran AE, Holzapfel KL, Xing Y, et al. T cell receptor signal strength in Treg and iNKT
cell development demonstrated by a novel fluorescent reporter mouse. J Exp Med
2011;208:1279–89.
27 Moran AE, Polesso F, Weinberg AD. Immunotherapy expands and maintains the function
of high-affinity tumor-infiltrating CD8 T cells in situ. J Immunol 2016;197:2509–21.
28 Powell DR, Huttenlocher A. Neutrophils in the tumor microenvironment. Trends
Immunol 2016;37:41–52.
29 Khaled YS, Ammori BJ, Elkord E. Increased levels of granulocytic myeloid-derived
suppressor cells in peripheral blood and tumour tissue of pancreatic cancer patients.
J Immunol Res 2014.doi: 10.1155/2014/879897.[Epub ahead of print 29 Jan 2014].
30 Porembka MR, Mitchem JB, Belt BA, et al. Pancreatic adenocarcinoma induces bone
marrow mobilization of myeloid-derived suppressor cells which promote primary
tumor growth. Cancer Immunol Immunother 2012;61:1373–85.
31	Templeton AJ, McNamara MG, Šeruga B, et al. Prognostic role of neutrophil-tolymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer
Inst 2014;106.
32 Paramanathan A, Saxena A, Morris DL. A systematic review and meta-analysis on
the impact of pre-operative neutrophil lymphocyte ratio on long term outcomes after
curative intent resection of solid tumours. Surg Oncol 2014;23:31–9.
33 Fossati G, Ricevuti G, Edwards SW, et al. Neutrophil infiltration into human gliomas.
Acta Neuropathol 1999;98:349–54.
34	Li A, King J, Moro A, et al. Overexpression of CXCL5 is associated with poor survival in
patients with pancreatic cancer. Am J Pathol 2011;178:1340–9.

Nywening TM, et al. Gut 2018;67:1112–1123. doi:10.1136/gutjnl-2017-313738

Gut: first published as 10.1136/gutjnl-2017-313738 on 1 December 2017. Downloaded from http://gut.bmj.com/ on 5 June 2018 by guest. Protected by copyright.

immunomodulatory therapies. Future studies should expand
beyond the current isolation of selective targeting of either
TAM or TAN and progress to multimodality strategies aimed
at elucidating the complex interactions among all inflammatory
cells within the TME. Importantly, the ability of tumours to
recruit additional myeloid populations should be considered as a
complementary target to enhance antitumour therapies.

Pancreas
43	Cameron DA, Massie C, Kerr G, et al. Moderate neutropenia with adjuvant CMF
confers improved survival in early breast cancer. Br J Cancer 2003;89:1837–42.
44 Sato H, Tsubosa Y, Kawano T. Correlation between the pretherapeutic neutrophil
to lymphocyte ratio and the pathologic response to neoadjuvant chemotherapy in
patients with advanced esophageal cancer. World J Surg 2012;36:617–22.
45	An X, Ding PR, Wang FH, et al. Elevated neutrophil to lymphocyte ratio predicts poor
prognosis in nasopharyngeal carcinoma. Tumour Biol 2011;32:317–24.
46 Kurihara T, Kogo M, Ishii M, et al. Chemotherapy-induced neutropenia as a prognostic
factor in patients with unresectable pancreatic cancer. Cancer Chemother Pharmacol
2015;76:1217–24.
47 Banerjee S, Rustin G, Paul J, et al. A multicenter, randomized trial of flat dosing versus
intrapatient dose escalation of single-agent carboplatin as first-line chemotherapy for
advanced ovarian cancer: an SGCTG (SCOTROC 4) and ANZGOG study on behalf of
GCIG. Ann Oncol 2013;24:679–87.
48	Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic
pancreatic cancer. N Engl J Med 2011;364:1817–25.
49	Guleria I, Pollard JW. Aberrant macrophage and neutrophil population dynamics
and impaired Th1 response to Listeria monocytogenes in colony-stimulating factor
1-deficient mice. Infect Immun 2001;69:1795–807.
50 Poo YS, Nakaya H, Gardner J, et al. CCR2 deficiency promotes exacerbated chronic
erosive neutrophil-dominated chikungunya virus arthritis. J Virol 2014;88:6862–72.



Nywening TM, et al. Gut 2018;67:1112–1123. doi:10.1136/gutjnl-2017-313738

1123

Gut: first published as 10.1136/gutjnl-2017-313738 on 1 December 2017. Downloaded from http://gut.bmj.com/ on 5 June 2018 by guest. Protected by copyright.

35	Nair P, Gaga M, Zervas E, et al. Safety and efficacy of a CXCR2 antagonist in patients
with severe asthma and sputum neutrophils: a randomized, placebo-controlled clinical
trial. Clin Exp Allergy 2012;42:1097–103.
36	Rennard SI, Dale DC, Donohue JF, et al. CXCR2 antagonist MK-7123. A phase 2 proofof-concept trial for chronic obstructive pulmonary disease. Am J Respir Crit Care Med
2015;191:1001–11.
37	Chen JJ, Lin YC, Yao PL, et al. Tumor-associated macrophages: the double-edged
sword in cancer progression. J Clin Oncol 2005;23:953–64.
38 DeNardo DG, Brennan DJ, Rexhepaj E, et al. Leukocyte complexity predicts breast
cancer survival and functionally regulates response to chemotherapy. Cancer Discov
2011;1:54–67.
39	Cassier PA, Italiano A, Gomez-Roca CA, et al. CSF1R inhibition with emactuzumab
in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a
dose-escalation and dose-expansion phase 1 study. Lancet Oncol 2015;16:949–56.
40	Tap WD, Wainberg ZA, Anthony SP, et al. Structure-Guided Blockade of CSF1R Kinase
in Tenosynovial Giant-Cell Tumor. N Engl J Med 2015;373:428–37.
41 Di Maio M, Gridelli C, Gallo C, et al. Chemotherapy-induced neutropenia and
treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of three
randomised trials. Lancet Oncol 2005;6:669–77.
42	Rocconi RP, Matthews KS, Kemper MK, et al. Chemotherapy-related myelosuppression as a
marker of survival in epithelial ovarian cancer patients. Gynecol Oncol 2008;108:336–41.

